JPWO2021075328A1 - - Google Patents
Info
- Publication number
- JPWO2021075328A1 JPWO2021075328A1 JP2021552347A JP2021552347A JPWO2021075328A1 JP WO2021075328 A1 JPWO2021075328 A1 JP WO2021075328A1 JP 2021552347 A JP2021552347 A JP 2021552347A JP 2021552347 A JP2021552347 A JP 2021552347A JP WO2021075328 A1 JPWO2021075328 A1 JP WO2021075328A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019189091 | 2019-10-16 | ||
| JP2019189091 | 2019-10-16 | ||
| PCT/JP2020/037986 WO2021075328A1 (ja) | 2019-10-16 | 2020-10-07 | てんかん治療用又は自閉症スペクトラム障害治療用外用剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021075328A1 true JPWO2021075328A1 (https=) | 2021-04-22 |
| JP7601398B2 JP7601398B2 (ja) | 2024-12-17 |
Family
ID=75537453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552347A Active JP7601398B2 (ja) | 2019-10-16 | 2020-10-07 | てんかん治療用又は自閉症スペクトラム障害治療用外用剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240058365A1 (https=) |
| EP (1) | EP4046637A4 (https=) |
| JP (1) | JP7601398B2 (https=) |
| CN (1) | CN114555081A (https=) |
| AU (1) | AU2020365665A1 (https=) |
| CA (1) | CA3153921A1 (https=) |
| WO (1) | WO2021075328A1 (https=) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| WO2012105521A1 (ja) * | 2011-01-31 | 2012-08-09 | 国立大学法人大阪大学 | 皮膚疾患を処置するための外用薬およびその製造方法 |
| WO2016152519A1 (ja) * | 2015-03-23 | 2016-09-29 | 国立大学法人大阪大学 | びまん性神経線維腫用の外用薬 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| CN104490873A (zh) * | 2014-11-25 | 2015-04-08 | 邹丽萍 | 一种治疗儿童结节性硬化症的药物 |
| US10765665B2 (en) * | 2015-11-24 | 2020-09-08 | Melin Jeffrey | Composition comprising combination of rapamycin and an activator of AMP kinase and use thereof for treating diseases |
-
2020
- 2020-10-07 US US17/766,728 patent/US20240058365A1/en active Pending
- 2020-10-07 CA CA3153921A patent/CA3153921A1/en active Pending
- 2020-10-07 CN CN202080072265.6A patent/CN114555081A/zh active Pending
- 2020-10-07 AU AU2020365665A patent/AU2020365665A1/en not_active Abandoned
- 2020-10-07 JP JP2021552347A patent/JP7601398B2/ja active Active
- 2020-10-07 WO PCT/JP2020/037986 patent/WO2021075328A1/ja not_active Ceased
- 2020-10-07 EP EP20876076.9A patent/EP4046637A4/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011526889A (ja) * | 2008-06-30 | 2011-10-20 | アフギン ファーマ，エルエルシー | 局所局部的神経作用療法 |
| WO2012105521A1 (ja) * | 2011-01-31 | 2012-08-09 | 国立大学法人大阪大学 | 皮膚疾患を処置するための外用薬およびその製造方法 |
| WO2016152519A1 (ja) * | 2015-03-23 | 2016-09-29 | 国立大学法人大阪大学 | びまん性神経線維腫用の外用薬 |
Non-Patent Citations (5)
| Title |
|---|
| CARDAMONE, M. ET AL.: ""Mammalian Target of Rapamycin Inhibitors for Intractable Epilepsy and Subependymal Giant Cell Astro", THE JOURNAL OF PEDIATRICS, vol. 164, no. 5, JPN6020049771, 2014, pages 1195 - 1200, ISSN: 0005405362 * |
| FRENCH, J. A. ET AL.: ""Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous", LANCET, vol. 388, JPN6020049769, 2016, pages 2153 - 2163, ISSN: 0005405360 * |
| ISHII, R. ET AL.: ""Everolimus improves behavioral deficits in a patient with autism associated with tuberous sclerosis", NEUROPSYCHIATRIC ELECTROPHYSIOLOGY, vol. 1: 6, JPN6020049773, 2015, pages 1 - 7, ISSN: 0005405364 * |
| KRUEGER, D. A. ET AL.: ""Everolimus Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex"", ANNALS OF NEUROLOGY, vol. 74, no. 5, JPN6020049770, 2013, pages 679 - 687, ISSN: 0005405361 * |
| SATO, A. ET AL.: ""Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex"", NATURE COMMUNICATIONS, vol. 3: 1292, JPN6020049772, 2012, pages 1 - 9, ISSN: 0005405363 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020365665A1 (en) | 2022-04-14 |
| WO2021075328A1 (ja) | 2021-04-22 |
| CN114555081A (zh) | 2022-05-27 |
| JP7601398B2 (ja) | 2024-12-17 |
| EP4046637A4 (en) | 2023-11-01 |
| CA3153921A1 (en) | 2021-04-22 |
| US20240058365A1 (en) | 2024-02-22 |
| EP4046637A1 (en) | 2022-08-24 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231002 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240902 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241018 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241120 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241128 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7601398 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |